Amends existing law to revise provisions regarding controlled substances.
House Bill 29 updates Idaho’s Uniform Controlled Substances Act by revising the state’s schedules of controlled substances, primarily Schedule I, Schedule III, and Schedule IV. The bill adds, updates, and reorganizes a large number of specific substances and chemical families, including many fentanyl analogs and related synthetic opioids, nitazenes, synthetic cannabinoids, hallucinogens, stimulants, depressants, and anabolic steroids. It also clarifies or expands definitions for certain classes of drugs, such as fentanyl-related substances and substituted cathinones, and retains exemptions for some FDA-approved products and certain industrial or veterinary uses.
The bill’s practical effect is to align Idaho’s controlled-substance lists with current drug trends and enforcement needs, giving law enforcement and prosecutors broader coverage against emerging synthetic drugs. It amends Idaho Code sections 37-2705, 37-2709, and 37-2711, which govern the classification of controlled substances and the legal consequences tied to possession, distribution, manufacture, and related conduct. The act includes an emergency clause and takes effect July 1, 2025, indicating the Legislature wanted the changes to apply quickly.
The overall sentiment around the bill appears strongly supportive and noncontroversial. It passed the House 70-0 and the Senate 35-0, suggesting broad bipartisan agreement that the controlled-substances schedules needed updating. The bill was introduced by the House Health and Welfare Committee, which is consistent with a public-health and drug-enforcement rationale.
There is little evidence of substantive opposition in the available record, and no committee transcript excerpts were provided showing debate. The main policy issue implicit in the bill is the balance between keeping pace with rapidly evolving synthetic drugs and avoiding overbroad criminalization of chemical analogs or legitimate medical and industrial products. The detailed chemical definitions, especially for fentanyl-related substances and synthetic cannabinoids, are the most likely areas where technical drafting precision matters, but the unanimous votes suggest no recorded contention at the floor level.
This bill amends Idaho Code sections 37-2705, 37-2709, and 37-2711 to revise the state’s controlled-substances schedules. It expands and updates the lists of Schedule I, III, and IV substances, including numerous fentanyl analogs, nitazenes, synthetic cannabinoids, hallucinogens, stimulants, depressants, anabolic steroids, and certain approved or exempted products. The changes affect criminal enforcement, prescribing, dispensing, manufacturing, possession, and trafficking under Idaho’s Uniform Controlled Substances Act, and the emergency clause makes the revisions effective July 1, 2025.
The bill appears to have received overwhelmingly positive and unanimous support. It passed both chambers without any recorded dissent, 70-0 in the House and 35-0 in the Senate. That voting pattern suggests a shared view that the controlled-substances schedules needed prompt updating to address emerging synthetic drugs and related public-safety concerns.
No explicit opposition is reflected in the available committee or floor record, and no committee transcript was provided. The likely points of contention, if any, would be technical rather than ideological: whether the chemical definitions are precise enough, whether the fentanyl-related-substances language is too broad, and whether legitimate medical, FDA-approved, agricultural, or industrial products are sufficiently exempted. Those concerns would primarily matter to law enforcement, prosecutors, pharmacists, medical providers, and manufacturers, but they did not appear to generate recorded disagreement in the votes provided.